Aa
6 months post treatment Lambda IL29 study = SVR
I just received my 6 month post treatment blood test results. I am SVR!!!
I'm also on a lambda trial that is made up of people who are type 1 and have the CC allele. I was und at 12 weeks (starting VL 17.5 million) and am waiting to see what my 24 week bloods show. (Total treatment time was 24 weeks.) At week 20, or after the EASL conference, our dosage was reduced from 240 mcg to 180 mcg per week as BMSquibb felt there was no significant difference in the outcomes of the 2 dosages. Riba dosing was weight dependent.
It was suggested at my last visit that it would be desirable that the lambda would prove capable of replacing the alpha interferon in both SOC and the new triple drug therapies. This was said in casual conversation by one of the researchers...
Like CoStudy, I know that I was very fortunate not to suffer the number of sides that many do on alpha and would encourage any looking for a study to try to get into one using lambda.
It was suggested at my last visit that it would be desirable that the lambda would prove capable of replacing the alpha interferon in both SOC and the new triple drug therapies. This was said in casual conversation by one of the researchers...
Like CoStudy, I know that I was very fortunate not to suffer the number of sides that many do on alpha and would encourage any looking for a study to try to get into one using lambda.
"Safety
In this study, rates of adverse events commonly associated with interferon treatment were lower with PEG-Interferon lambda than with PEG-Interferon alfa. These adverse events included flu-like symptoms (lambda 240 mcg: 9.7%; lambda 180 mcg: 9.9%; lambda 120 mcg: 12.5%; alfa: 42.9%), musculoskeletal symptoms (lambda 240 mcg: 14.2%; lambda 180 mcg: 14.5%; lambda 120 mcg: 18.0%; alfa: 46.6%), neutropenia < 750/mm3 (lambda 240 mcg: 0.0%; lambda 180 mcg: 0.8%; lambda 120 mcg: 0.0%; alfa: 15.2%), anemia with hemoglobin < 10 g/dL (lambda 240 mcg: 12.9%; lambda 180 mcg: 15.4%; lambda 120 mcg: 20.5%; alfa: 43.9%.) and thrombocytopenia 10%) were similar across treatment arms. Higher rates of elevated liver enzymes [AST or ALT >5x the upper limit of normal (ULN)] were seen in the highest-dose PEG-Interferon lambda treatment arm compared with PEG-Interferon alfa (lambda 240 mcg: 17.4%; lambda 180 mcg: 2.3%; lambda 120 mcg: 0.8%; alfa: 7.6%), and direct bilirubin was also elevated (>1.2 mg/dL) in the highest-dose PEG-Interferon lambda treatment arm compared with PEG-Interferon alfa (lambda 240 mcg: 7.6%; lambda 180 mcg: 3.9%; lambda 120 mcg: 0.8%; alfa: 0.8%); all resolved spontaneously without sequelae or following interferon dose modification and/or discontinuation."
I hope you don't mind my posting all this on your thread, but it certainly seemed relevant.
-Dave
In this study, rates of adverse events commonly associated with interferon treatment were lower with PEG-Interferon lambda than with PEG-Interferon alfa. These adverse events included flu-like symptoms (lambda 240 mcg: 9.7%; lambda 180 mcg: 9.9%; lambda 120 mcg: 12.5%; alfa: 42.9%), musculoskeletal symptoms (lambda 240 mcg: 14.2%; lambda 180 mcg: 14.5%; lambda 120 mcg: 18.0%; alfa: 46.6%), neutropenia < 750/mm3 (lambda 240 mcg: 0.0%; lambda 180 mcg: 0.8%; lambda 120 mcg: 0.0%; alfa: 15.2%), anemia with hemoglobin < 10 g/dL (lambda 240 mcg: 12.9%; lambda 180 mcg: 15.4%; lambda 120 mcg: 20.5%; alfa: 43.9%.) and thrombocytopenia 10%) were similar across treatment arms. Higher rates of elevated liver enzymes [AST or ALT >5x the upper limit of normal (ULN)] were seen in the highest-dose PEG-Interferon lambda treatment arm compared with PEG-Interferon alfa (lambda 240 mcg: 17.4%; lambda 180 mcg: 2.3%; lambda 120 mcg: 0.8%; alfa: 7.6%), and direct bilirubin was also elevated (>1.2 mg/dL) in the highest-dose PEG-Interferon lambda treatment arm compared with PEG-Interferon alfa (lambda 240 mcg: 7.6%; lambda 180 mcg: 3.9%; lambda 120 mcg: 0.8%; alfa: 0.8%); all resolved spontaneously without sequelae or following interferon dose modification and/or discontinuation."
I hope you don't mind my posting all this on your thread, but it certainly seemed relevant.
-Dave
"Study Results
Viral Response: HCV Genotypes 1 and 4
In this study, HCV genotype 1 and 4 patients treated with PEG-Interferon lambda achieved statistically significant (p<0.05) higher rates of cEVR (primary study endpoint) versus PEG-Interferon alfa at all doses [lambda 240 mcg: 56.3% (n=103), lambda 180 mcg: 55.9% (n=102), lambda 120 mcg: 55.0% (n=100) vs. alfa: 37.9% (n=103)]. These statistically significant (p<0.05) higher viral response rates were seen as early as four weeks of treatment, with greater rates of RVR at the two higher doses of PEG-Interferon lambda (lambda 240 mcg: 16.5%, lambda 180 mcg: 14.7%, lambda 120 mcg: 6.0% vs. alfa: 5.8%).
Viral Response: HCV Genotypes 2 and 3
In patients with HCV genotypes 2 and 3, treatment with all doses of PEG-Interferon lambda achieved cEVR rates similar to PEG-Interferon alfa [lambda 240 mcg: 83.3% (n=30), lambda 180 mcg: 96.6% (n=29), lambda 120 mcg: 90% (n=30), and alfa: 86.2%, (n=29)]. Statistically significant (p<0.05) higher rates of RVR were achieved at the two higher doses of PEG-Interferon lambda (lambda 240 mcg: 66.7%, lambda 180 mcg: 75.9%, lambda 120 mcg: 43.3% vs. alfa: 31%)."
Viral Response: HCV Genotypes 1 and 4
In this study, HCV genotype 1 and 4 patients treated with PEG-Interferon lambda achieved statistically significant (p<0.05) higher rates of cEVR (primary study endpoint) versus PEG-Interferon alfa at all doses [lambda 240 mcg: 56.3% (n=103), lambda 180 mcg: 55.9% (n=102), lambda 120 mcg: 55.0% (n=100) vs. alfa: 37.9% (n=103)]. These statistically significant (p<0.05) higher viral response rates were seen as early as four weeks of treatment, with greater rates of RVR at the two higher doses of PEG-Interferon lambda (lambda 240 mcg: 16.5%, lambda 180 mcg: 14.7%, lambda 120 mcg: 6.0% vs. alfa: 5.8%).
Viral Response: HCV Genotypes 2 and 3
In patients with HCV genotypes 2 and 3, treatment with all doses of PEG-Interferon lambda achieved cEVR rates similar to PEG-Interferon alfa [lambda 240 mcg: 83.3% (n=30), lambda 180 mcg: 96.6% (n=29), lambda 120 mcg: 90% (n=30), and alfa: 86.2%, (n=29)]. Statistically significant (p<0.05) higher rates of RVR were achieved at the two higher doses of PEG-Interferon lambda (lambda 240 mcg: 66.7%, lambda 180 mcg: 75.9%, lambda 120 mcg: 43.3% vs. alfa: 31%)."
http://www.hivandhepatitis.com/2011_conference/easl2011/docs/0404_2010_b.html
"Princeton, N.J. -- April 2, 2011 -- Bristol-Myers Squibb Company (NYSE: BMY) today announced results from the Phase IIb EMERGE clinical trial, in which treatment with the investigational compound PEG-Interferon lambda and ribavirin achieved higher rates of rapid virologic response (RVR) [undetectable viral load (HCV RNA 10%) were similar across treatment arms up to week 12.
The EMERGE study findings were presented in a late-breaker oral session at the International Liver Congress (ILC), the 46th annual meeting of the European Association for the Study of the Liver (EASL) in Berlin, Germany.
"Princeton, N.J. -- April 2, 2011 -- Bristol-Myers Squibb Company (NYSE: BMY) today announced results from the Phase IIb EMERGE clinical trial, in which treatment with the investigational compound PEG-Interferon lambda and ribavirin achieved higher rates of rapid virologic response (RVR) [undetectable viral load (HCV RNA 10%) were similar across treatment arms up to week 12.
The EMERGE study findings were presented in a late-breaker oral session at the International Liver Congress (ILC), the 46th annual meeting of the European Association for the Study of the Liver (EASL) in Berlin, Germany.
Thank you for your replies.
Trish77 & Spectda
I do not know what my dosage was taking. The study is still going. I am G2 and one of the first to start Phase IIB of the study. They will release all information after everyone is done with treatment and the 6 month followup. I was taking 800mg of Riba every day and the injection amount I am unsure of. They will not even tell me when I was UD other than I was UD at 12 weeks. If you were not UD at 12 weeks they would remove you from the study. As stated in earlier posts, I feel guilty because I had very few sx. I look back today and think how frickin lucky I was to be in this study. I hope people looking for studies keep their eyes open for the phase 3 part of the study that should start in the next year or so. Lambda and the new PI's could be a short term minor sx treatment in the future. Who knows..
Trish77 & Spectda
I do not know what my dosage was taking. The study is still going. I am G2 and one of the first to start Phase IIB of the study. They will release all information after everyone is done with treatment and the 6 month followup. I was taking 800mg of Riba every day and the injection amount I am unsure of. They will not even tell me when I was UD other than I was UD at 12 weeks. If you were not UD at 12 weeks they would remove you from the study. As stated in earlier posts, I feel guilty because I had very few sx. I look back today and think how frickin lucky I was to be in this study. I hope people looking for studies keep their eyes open for the phase 3 part of the study that should start in the next year or so. Lambda and the new PI's could be a short term minor sx treatment in the future. Who knows..
Congrats on your SVR !!.....this seems to be another product in the pipeline with good results.!
Best...
Will
What wonderful news on the SVR with the lambda. Is the study complete now or are people still treating?
Take care,
Dave
Take care,
Dave
That is fabulous!! Would you mind posting what your dosages were throughout the trial and details? Good info for anyone reading this! Congratulations to you!
Trish
Trish
Wow CONGRATULATIONS!!!
Way to go!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Enjoy your new life free and clear of HCV.
All the best -
Hectorsf
Way to go!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Enjoy your new life free and clear of HCV.
All the best -
Hectorsf
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
